Free Trial

Valneva (VALN) Competitors

Valneva logo
$9.57 -0.11 (-1.10%)
As of 10/24/2025 04:00 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

VALN vs. ADMA, INDV, AAPG, XENE, QURE, ZLAB, CGON, RARE, IRON, and AMRX

Should you be buying Valneva stock or one of its competitors? The main competitors of Valneva include ADMA Biologics (ADMA), Indivior (INDV), Ascentage Pharma Group International (AAPG), Xenon Pharmaceuticals (XENE), uniQure (QURE), Zai Lab (ZLAB), CG Oncology (CGON), Ultragenyx Pharmaceutical (RARE), Disc Medicine (IRON), and AMNEAL PHARMACEUTICALS (AMRX). These companies are all part of the "pharmaceutical products" industry.

Valneva vs. Its Competitors

Valneva (NASDAQ:VALN) and ADMA Biologics (NASDAQ:ADMA) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, risk, earnings, valuation, media sentiment, profitability, analyst recommendations and dividends.

Valneva has a beta of 1.86, meaning that its share price is 86% more volatile than the S&P 500. Comparatively, ADMA Biologics has a beta of 0.47, meaning that its share price is 53% less volatile than the S&P 500.

In the previous week, ADMA Biologics had 2 more articles in the media than Valneva. MarketBeat recorded 9 mentions for ADMA Biologics and 7 mentions for Valneva. ADMA Biologics' average media sentiment score of 0.93 beat Valneva's score of 0.55 indicating that ADMA Biologics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Valneva
1 Very Positive mention(s)
1 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
ADMA Biologics
5 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive

ADMA Biologics has a net margin of 44.06% compared to Valneva's net margin of -33.87%. ADMA Biologics' return on equity of 41.01% beat Valneva's return on equity.

Company Net Margins Return on Equity Return on Assets
Valneva-33.87% -34.78% -13.43%
ADMA Biologics 44.06%41.01%28.47%

11.4% of Valneva shares are held by institutional investors. Comparatively, 75.7% of ADMA Biologics shares are held by institutional investors. 14.9% of Valneva shares are held by insiders. Comparatively, 3.5% of ADMA Biologics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Valneva currently has a consensus price target of $15.00, indicating a potential upside of 57.07%. ADMA Biologics has a consensus price target of $27.67, indicating a potential upside of 82.26%. Given ADMA Biologics' stronger consensus rating and higher probable upside, analysts plainly believe ADMA Biologics is more favorable than Valneva.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Valneva
1 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.50
ADMA Biologics
0 Sell rating(s)
1 Hold rating(s)
2 Buy rating(s)
1 Strong Buy rating(s)
3.00

ADMA Biologics has higher revenue and earnings than Valneva. Valneva is trading at a lower price-to-earnings ratio than ADMA Biologics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Valneva$183.52M4.47-$13.25M-$0.98-9.74
ADMA Biologics$426.45M8.49$197.67M$0.8617.65

Summary

ADMA Biologics beats Valneva on 14 of the 17 factors compared between the two stocks.

Get Valneva News Delivered to You Automatically

Sign up to receive the latest news and ratings for VALN and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding VALN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

VALN vs. The Competition

MetricValnevaMED PRODUCTS IndustryMedical SectorNASDAQ Exchange
Market Cap$820.60M$11.08B$6.21B$10.81B
Dividend YieldN/A1.88%5.72%4.80%
P/E Ratio-9.7421.4531.6030.99
Price / Sales4.4731.07595.06133.64
Price / Cash97.7425.0837.2561.86
Price / Book3.963.5012.056.61
Net Income-$13.25M$210.63M$3.34B$277.10M
7 Day Performance-5.08%0.74%1.94%2.57%
1 Month Performance-1.65%2.73%6.88%3.20%
1 Year Performance60.77%-7.76%56.06%33.22%

Valneva Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
VALN
Valneva
3.1144 of 5 stars
$9.55
-1.3%
$15.00
+57.1%
+60.8%$820.60M$183.52M-9.74700Analyst Forecast
Short Interest ↓
ADMA
ADMA Biologics
3.6064 of 5 stars
$14.69
+2.3%
$27.67
+88.3%
-4.0%$3.43B$426.45M17.08530News Coverage
Positive News
Analyst Downgrade
INDV
Indivior
2.0604 of 5 stars
$24.29
-0.8%
$22.00
-9.4%
+179.2%$3.38B$1.17B39.181,051Upcoming Earnings
AAPG
Ascentage Pharma Group International
N/A$35.31
-0.4%
N/AN/A$3.30B$134.35M0.00600Positive News
XENE
Xenon Pharmaceuticals
2.7366 of 5 stars
$43.44
+4.3%
$53.67
+23.5%
-2.3%$3.21B$9.43M-12.24210
QURE
uniQure
2.9678 of 5 stars
$63.92
+10.2%
$71.75
+12.2%
+833.6%$3.18B$27.12M-16.31500Analyst Forecast
Gap Up
ZLAB
Zai Lab
2.7291 of 5 stars
$28.74
+1.6%
$56.35
+96.1%
-18.7%$3.16B$398.99M-14.091,869News Coverage
Analyst Forecast
Analyst Revision
CGON
CG Oncology
2.1089 of 5 stars
$43.59
+5.1%
$58.82
+34.9%
+20.0%$3.16B$1.14M-24.6361Analyst Forecast
RARE
Ultragenyx Pharmaceutical
4.4789 of 5 stars
$34.40
+5.4%
$82.27
+139.2%
-37.7%$3.15B$560.23M-6.221,294News Coverage
Analyst Forecast
IRON
Disc Medicine
2.8083 of 5 stars
$87.17
-3.1%
$108.73
+24.7%
+86.1%$3.13BN/A-19.5030Trending News
Analyst Forecast
Analyst Revision
High Trading Volume
AMRX
AMNEAL PHARMACEUTICALS
2.3981 of 5 stars
$10.24
+3.2%
$12.00
+17.2%
+25.6%$3.12B$2.79B1,025.038,100Analyst Forecast

Related Companies and Tools


This page (NASDAQ:VALN) was last updated on 10/26/2025 by MarketBeat.com Staff
From Our Partners